Actively Recruiting
Genomic Predictors of Papillary Microcarcinoma Disease Progression
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-03-12
750
Participants Needed
1
Research Sites
678 weeks
Total Duration
On this page
Sponsors
M
Memorial Sloan Kettering Cancer Center
Lead Sponsor
O
Ohio State University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study is being done to answer the following question: What are the specific clinical and molecular features that will help us predict which small thyroid cancers are likely to grow and be problematic? Therefore, the purpose of this study is to identify specific clinical and molecular characteristics that are predictive of tumor progression in small thyroid cancers.
CONDITIONS
Official Title
Genomic Predictors of Papillary Microcarcinoma Disease Progression
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Biopsy proven papillary thyroid cancer or suspicion confirmed by MSKCC cytopathologist
- Currently followed with active surveillance at MSKCC
- Biopsied tumor 2 cm or smaller in maximum dimension
- Thyroid and neck ultrasound performed and interpreted by MSKCC radiologist within 6 months before study entry
You will not qualify if you...
- Biopsied tumor larger than 2 cm in any dimension
- Age younger than 18 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
Research Team
R
Robert Tuttle, MD
CONTACT
M
Michael Berger, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here